MX2012002847A - Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos. - Google Patents

Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.

Info

Publication number
MX2012002847A
MX2012002847A MX2012002847A MX2012002847A MX2012002847A MX 2012002847 A MX2012002847 A MX 2012002847A MX 2012002847 A MX2012002847 A MX 2012002847A MX 2012002847 A MX2012002847 A MX 2012002847A MX 2012002847 A MX2012002847 A MX 2012002847A
Authority
MX
Mexico
Prior art keywords
enzyme
ketone
compositions
prodrug
modified opioid
Prior art date
Application number
MX2012002847A
Other languages
English (en)
Other versions
MX348262B (es
Inventor
Thomas E Jenkins
Julie D Seroogy
Jonathan W Wray
Craig O Husfeld
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of MX2012002847A publication Critical patent/MX2012002847A/es
Publication of MX348262B publication Critical patent/MX348262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un método para proporcionar un paciente con liberación controlada de opoide que contienen cetona utilizando un profármaco capaz, tras la activación enzimática y ciclación intramolecular, de liberar el opioide que contiene cetona. La descripción también proporciona tales compuestos de profármacos y composiciones farmacéuticas que comprenden tales compuestos. Tales composiciones farmacéuticas pueden incluir opcionalmente un inhibidor enzimático que interactúa con las enzimas para mediar la liberación controlada enzimáticamente del opioide que contiene cetona del profármaco así como para modificar la separación enzimática del profármaco. También se incluyen métodos para usar tales compuestos y composiciones farmacéuticas.
MX2012002847A 2009-09-08 2010-04-21 Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos. MX348262B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24061109P 2009-09-08 2009-09-08
US28814809P 2009-12-18 2009-12-18
PCT/US2010/031956 WO2011031350A1 (en) 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Publications (2)

Publication Number Publication Date
MX2012002847A true MX2012002847A (es) 2012-08-23
MX348262B MX348262B (es) 2017-06-05

Family

ID=43732738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002847A MX348262B (es) 2009-09-08 2010-04-21 Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.

Country Status (13)

Country Link
US (2) US9493477B2 (es)
EP (1) EP2475429B1 (es)
JP (3) JP2013503862A (es)
CN (1) CN102695545B (es)
AU (1) AU2010293028B2 (es)
BR (1) BR112012005124B1 (es)
CA (1) CA2773340C (es)
HK (1) HK1172283A1 (es)
IL (1) IL218498A (es)
MX (1) MX348262B (es)
RU (1) RU2600736C2 (es)
SG (1) SG179026A1 (es)
WO (1) WO2011031350A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493477B2 (en) * 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
CN102917589A (zh) * 2010-04-21 2013-02-06 特色疗法股份有限公司 包含酶可剪切的阿片样物质的药物前体和其抑制剂的组合物
EP2560486B1 (en) 2010-04-21 2018-11-21 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
CH705273B1 (de) 2010-05-10 2016-06-15 Euro Celtique Sa Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
KR101479388B1 (ko) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. 활성제 로딩된 과립과 추가의 활성제와의 조합물
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
ES2584634T3 (es) * 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
EP2760844B1 (fr) * 2011-09-29 2018-11-21 Ecole Normale Superieure De Lyon Substrat de peptidase fluorogene
IN2014DN03009A (es) 2011-10-26 2015-05-08 Kempharm Inc
SG11201602884WA (en) 2013-11-13 2016-05-30 Euro Celtique Sa Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CN112043835B (zh) * 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
SG11201704309YA (en) 2014-12-02 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
HUE055305T2 (hu) * 2017-11-24 2021-11-29 Byondis Bv Javított eljárás vc-seco linker-hatóanyag szintézisére
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
TW202019887A (zh) * 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
EP0893437A4 (en) 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
JP4668418B2 (ja) 1998-12-15 2011-04-13 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー 多種酵素アッセイ
AU3000800A (en) * 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US6897034B2 (en) * 2001-06-11 2005-05-24 Medarex, Inc. CD10-activated prodrug compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
WO2005047898A2 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
DK1644019T4 (en) 2003-05-29 2018-04-23 Shire Llc AMPHETAMINE COMPOUNDS RESISTANT TO ABUSE
EA008864B1 (ru) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
FR2881363B1 (fr) * 2005-02-02 2008-03-14 Commissariat Energie Atomique Dispositif d'analyses biologiques avec detecteur integre
WO2007022535A2 (en) 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
EP2179741B1 (en) 2005-08-26 2014-10-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administraton of oxytocin
AU2006299424A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
NZ569485A (en) 2005-12-05 2011-06-30 Xenoport Inc Levodopa prodrug mesylate, compositions thereof, and uses thereof
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
AU2007238625A1 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
KR20090031519A (ko) 2006-05-26 2009-03-26 파마코포어, 인크. 페놀계 오피오이드의 제어 방출
WO2008101202A1 (en) 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
US20110105381A2 (en) 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
US9023860B2 (en) * 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009080030A1 (en) 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
JP2011512360A (ja) * 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
EP3275460A1 (en) 2008-05-05 2018-01-31 Oramed Ltd. Methods and compositions for oral administration of exenatide
MX2011004095A (es) 2008-10-17 2011-07-28 Pharmacofore Inc Composiciones farmaceuticas con liberacion atenuada de opioides fenolicos.
CA2756397A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
WO2011007247A1 (en) 2009-07-17 2011-01-20 Llc Shire Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
US9493477B2 (en) * 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110262355A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
CN102917589A (zh) * 2010-04-21 2013-02-06 特色疗法股份有限公司 包含酶可剪切的阿片样物质的药物前体和其抑制剂的组合物
EP2560491A1 (en) 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Peripheral opioid agonists and peripheral opioid antagonists
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
ES2584634T3 (es) * 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
CA2827662C (en) * 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) * 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers

Also Published As

Publication number Publication date
EP2475429B1 (en) 2015-07-29
EP2475429A1 (en) 2012-07-18
MX348262B (es) 2017-06-05
BR112012005124A2 (pt) 2020-08-25
CA2773340A1 (en) 2011-03-17
EP2475429A4 (en) 2013-04-03
WO2011031350A1 (en) 2011-03-17
AU2010293028B2 (en) 2014-12-18
SG179026A1 (en) 2012-04-27
JP2013503862A (ja) 2013-02-04
JP6778234B2 (ja) 2020-10-28
HK1172283A1 (zh) 2013-04-19
CN102695545B (zh) 2016-08-17
JP2018172387A (ja) 2018-11-08
CN102695545A (zh) 2012-09-26
US10028945B2 (en) 2018-07-24
IL218498A0 (en) 2012-07-31
AU2010293028A1 (en) 2012-04-05
CA2773340C (en) 2019-07-23
JP2016041698A (ja) 2016-03-31
RU2600736C2 (ru) 2016-10-27
US20170119754A1 (en) 2017-05-04
US20120230916A1 (en) 2012-09-13
RU2012108874A (ru) 2013-09-20
BR112012005124B1 (pt) 2021-11-09
IL218498A (en) 2017-03-30
US9493477B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
SG179026A1 (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
SG190819A1 (en) Nampt and rock inhibitors
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
TN2010000203A1 (en) Beta-lactamase inhibitors
MX2020005498A (es) Inhibidores de cdk.
EP2477985A4 (en) CANCER TREATMENT
WO2012122420A3 (en) Opioid prodrugs with heterocyclic linkers
MX342851B (es) Metodos y materiales para sintesis enzimatica de compuestos mogrosido.
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
MX2009010568A (es) Formas solidas de pemetrexed.
IN2014CN03597A (es)
AP2011005682A0 (en) Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases.
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
LT2483271T (lt) Pirazolindiono dariniai, kaip nadph oksidazės inhibitoriai
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
MX348311B (es) Inhibidores nampt.
MX2012001617A (es) Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1.
ZA201204583B (en) Degradable removable implant for the sustained release of an active compound
IN2012DN03404A (es)
WO2009158646A8 (en) Therapeutic compounds and related methods of use
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration